康缘药业：获得运脾化痰通窍颗粒药物临床试验批准通知书

Core Viewpoint - Kangyuan Pharmaceutical (600557) has received approval from the National Medical Products Administration for clinical trials of its product aimed at treating children's adenoid hypertrophy with spleen deficiency and phlegm obstruction, which could fill a clinical gap in this area [1] Group 1: Product Development - The approved product is a traditional Chinese medicine formulation designed to promote spleen function, resolve phlegm, and open the orifices [1] - Currently, there are no approved traditional Chinese medicines for treating children's adenoid hypertrophy, which primarily relies on chemical drugs such as nasal corticosteroids, leukotriene receptor antagonists, antihistamines, and immunomodulators [1] Group 2: Market Potential - The successful launch of this product could significantly enhance clinical value and address an unmet medical need in pediatric care [1]